Related Experiment Video
Updated: May 30, 2025
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.6K
Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors.
Marie Yan1,2, Alejandro Hernandez3, Kelvin K Chan3,4
1Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Summary
This study found no significant link between immune checkpoint inhibitors and nontuberculous mycobacterial disease in cancer patients. Further research may explore potential risks in specific patient groups.
Area of Science:
- Oncology
- Infectious Diseases
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are a cornerstone of modern cancer therapy.
- Nontuberculous mycobacterial (NTM) disease is an opportunistic infection.
- The association between ICI use and NTM disease risk remains unclear.
Purpose of the Study:
- To investigate the potential association between the use of immune checkpoint inhibitors and the risk of developing nontuberculous mycobacterial disease.
- To evaluate the safety profile of immune checkpoint inhibitors concerning infectious complications.
Main Methods:
- Population-based study utilizing a nested case-control design.
- Inclusion of 184 cases of nontuberculous mycobacterial disease and 714 matched controls.
- Conditional logistic regression analysis to assess the association.
Main Results:
- No statistically significant association was observed between immune checkpoint inhibitor use and nontuberculous mycobacterial disease.
- The adjusted odds ratio was 0.51 (95% confidence interval, 0.17-1.50), with a P-value of .22.
Conclusions:
- Current evidence does not support a significant increased risk of nontuberculous mycobacterial disease in cancer patients treated with immune checkpoint inhibitors.
- The findings suggest that immune checkpoint inhibitors may not be a major risk factor for this specific opportunistic infection.
